Cancer immunoediting and dioxin-activating aryl hydrocarbon receptor: A missing link in the shift toward tumor immunoescape?

Journal of Nucleic Acids Investigation

Volumn 1, Issue 1, 2010, Pages 24-30

  Ridolfi, Ruggero ^a   Guidoboni, Massimo ^a   Ridolfi, Laura ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Aryl hydrocarbon receptor (AhR); Cancer immunoediting; Dioxin; T reg lymphocytes; Tumor immunoescape

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; CD4 ANTIGEN; CD8 ANTIGEN; DIOXIN; DIOXIN ACTIVATING ARYL HYDROCARBON RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; APOPTOSIS; B LYMPHOCYTE; BIOACCUMULATION; CANCER CELL; CANCER GROWTH; CANCER IMMUNOLOGY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL CYCLE REGULATION; CELL EXPANSION; CELL GROWTH; CELL LOSS; CELL TRANSFORMATION; CELLULAR IMMUNITY; CHEMICAL CARCINOGENESIS; DENDRITIC CELL; DISEASE ACTIVITY; FOOD CONTAMINATION; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; INDUSTRIAL WASTE; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; REVIEW; THYMOCYTE;

ANIMALIA; DROSOPHILA MELANOGASTER; MAMMALIA; NEMATODA;

EID: 79952590690     PISSN: None     EISSN: 20356005     Source Type: Journal    
DOI: 10.4081/jnai.2010.e6     Document Type: Review

References (127)

1. Ichim CV. Revisiting immunosurveillance and immunostimulation: implications for cancer immunotherapy. J Transl Med 2005; 3:8.
2. Topalian SL, Rosenberg SA. Tumor specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142: 3714-25.
3. Boon T, Cerottini JC, van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Ann Rev Immunol 1994;12:337-65.
4. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-39.
5. Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007;16:755-74, viii.
6. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904-12.
7. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
8. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunit 2004;21:137-48.
9. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117: 1137-46.
10. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-7.
11. Marincola FM, Jaffee EM, Hicklin JD, et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
12. Campoli M, Ferrone S, Zea AH, et al. Mechanisms of tumor evasion. Cancer Treat Res 2005;123:61-88.
13. Drake CG, Jaffee E, Pardoll DM. Mechan-isms of immune evasion by tumors. Adv Immunol 2006;90:51-81.
14. Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer. Clin Cancer Res 2003;9:4296-303.
15. Foss FM. Immunologic mechanisms of antitumor activity. Semin Oncol 2002;29: S5-11.
16. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004:10:48-54.
17. Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol 2005;175:1373-81.
18. Mocellin S, Wang E, Marincola FM. Cyto-kines and immune response in the tumor microenvironment. J Immunother 2001;24:392-407.
19. Dougan M, Dranoff G. Inciting inflammation: the RAGE about tumor promotion. J Exp Med 2008;205:267-70.
20. Davidson-Moncada J, Papavasiliou FN, Tam W. MicroRNAs of the immune system. Roles in inflammation and cancer. Ann NY Acad Sci 2010;1183:183-94.
21. Maldonado-Lopez R, Moser M. Dendritic cell subsets and regulation of Th1/Th2 responses. Semin Immunol 2001;13:275-82.
22. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
23. Muller AJ, Melachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 2005;9:831-49.
24. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53-65.
25. Ochoa AC, Zea AH, Hernandez C, et al. Arginase, prostaglandins, and myeloidderived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007;13:721-6s.
26. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117:1155-66.
27. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007;25:2546-53.
28. Levings MK, Sangregorio R, Sartirana C, et al. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 2002;196:1335-46.
29. Terabe M, Berzofsky JA. Immunore-gulatory T cells in tumor immunity. Curr Opin Immunol 2004;16:157-62.
30. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-9.
31. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117: 1167-74.
32. Andreola G, Rivoltini L, Castelli C, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303-16.
33. Martinez-Lorenzo MJ, Anel A, Alava MA, et al. The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 2004;295:315-29.
34. Whiteside TL. Tricks tumors use to escape from immune control. Oral Oncol 2009; 45:119-23.
35. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-54.
36. Whiteside TL, Rabinowich H. The role of Fas/FasL in immuno-suppression induced by human tumors. Cancer Immunol Immunother 1998;46:175-84.
37. Bron LP, Scolyer RA, Thompson JF, et al. Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology 2004;36:561-5.
38. Butte MJ, Peña-Cruz V, Kim MJ, et al. Interaction of human PD-L1 and B7-1. Mol Immunol 2008;45:3567-72.
39. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
40. Shurin MR. Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 1996;43:158-64.
41. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001;106:263-6.
42. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-8.
43. Munn DH. Tolerogenic antigen-presenting cells. Ann NY Acad Sci 2002;961:343-5.
44. Esser C, Rannug A, Stockinger B. The aryl hydrocarbon receptor in immunity. Trends Immunol 2009;30:447-54.
45. Schecter A, Birnbaum L, Ryan JJ, et al. Dioxins: an overview. Environ Res 2006; 101:419-28.
46. Hahn ME. The aryl hydrocarbon receptor: a comparative perspective. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998;121:23-53.
47. Hahn ME. Aryl hydrocarbon receptors: diversity and evolution. Chem Biol Interact 2002;141:131-60.
48. Elferink CJ. Aryl hydrocarbon receptormediated cell cycle control. Prog Cell Cycle Res 2003;5:261-7.
49. Marlowe JL, Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J Cell Biochem 2005;96: 1174-84.
50. Marshall NB, Kerkvliet NI. Dioxin and immune regulation. Emerging role of aryl hydrocarbon receptor in the generation of regulatory T cells. Ann NY Acad Sci 2010; 1183:25-37.
51. Stockinger B, Veldhoen M, Hirota K. Modulation of Th17 development and function by activation of the aryl hydrocarbon receptor--the role of endogenous ligands. Eur J Immunol 2009;39:652-4.
52. Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 2003;1619:263-8.
53. Bohonowych JE, Denison MS. Persistent binding of ligands to the aryl hydrocarbon receptor. Toxicol Sci 2007;98:99-109.
54. Stevens EA, Mezrich JD, Bradfield CA. The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology 2009;127:299-311.
55. Kerkvliet NI. Recent advances in understanding the mechanisms of TCDD immunotoxicity. Int Immunopharmacol 2002;2:277-91.
56. Lawrence BP, Kerkvliet NI. Immune modulation by TCDD and related polyhalogenated aromatic hydrocarbons. In: Immunotoxicology and immunopharmacology. Luebke R, House R, Kimber I, eds. Boca Raton (FL): CRC Press; 2006, pp 239-58.
57. Vorderstrasse BA, Steppan LB, Silverstone AE, et al. Aryl hydrocarbon receptor-deficient mice generate normal immune responses to model antigens and are resistant to TCDD-induced immune suppression. Toxicol Appl Pharmacol 2001; 171:157-64.
58. Lawrence BP, Roberts AD, Neumiller JJ, et al. Aryl hydrocarbon receptor activation impairs the priming but not the recall of influenza virus-specific CD8+ T cells in the lung. J Immunol 2005;177:5819-28.
59. Teske S, Bohn AA, Regal JF, et al. Exploring mechanisms that underlie aryl hydrocarbon receptor-mediated increases in pulmonary neutrophilia and diminished host resistance to influenza A virus. Am J Physiol Lung Cell Mol Physiol 2005;289: 111-24.
60. Kerkvliet NI. Immunological effects of chlorinated dibenzo-p-dioxins. Environ Health Perspect 1995;103:S47-53.
61. Kerkvliet NI, Baecher-Steppan L, Shepherd DM, et al. Inhibition of TC-1 cytokine production, effector cytotoxic T lymphocyte development and alloantibody production by 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Immunol 1996;157:2310-9.
62. Ito T, Inouye K, Fujimaki H, et al. Mechanism of TCDD-induced suppression of antibody production: effect on T cellderived cytokine production in the primary immune reaction of mice. Toxicol Sci 2002;70:46-54.
63. Allan LL, Sherr DH. Constitutive activation and environmental chemical induction of the aryl hydrocarbon receptor/transcription factor in activated human B lymphocytes. Mol Pharmacol 2005;67:1740-50.
64. Laiosa MD, Wyman A, Murante FG, et al. Cell proliferation arrest within intrathymic lymphocyte progenitor cells causes thymic atrophy mediated by the aryl hydrocarbon receptor. J Immunol 2003;171: 4582-91.
65. Temchura VV, Frericks M, Nacken W, et al. Role of the aryl hydrocarbon receptor in thymocyte emigration in vivo. Eur J Immunol 2005;35:2738-47.
66. McMillan BJ, McMillan SN, Glover E, et al. 2,3,7,8-tetrachlorodibenzo-p-dioxin induces premature activation of the KLF2 regulon during thymocyte development. J Biol Chem 2007;282:12590-7.
67. Fisher MT, Nagarkatti M, Nagarkatti PS. Combined screening of thymocytes using apoptosis-specific cDNA array and promoter analysis yields novel gene targets mediating TCDD-induced toxicity. Toxicol Sci 2004;78:116-24.
68. Camacho I, Singh N, Hegde V, et al. Treatment of mice with 2,3,7,8-tetrachlorodibenzo-p-dioxin leads to aryl hydrocarbon receptor-dependent nuclear translocation of NF-kappa B and expression of fas ligand in thymic stromal cells and consequent T cell apoptosis. J Immunol 2005;175:90-103.
69. Fine J, Gasiewicz T, Silverstone A. Lymphocyte stem cell alterations following perinatal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Mol Pharmacol 1989;35:18-25.
70. Nohara K, Jujimaki H, Tsukumo S, et al. The effects of perinatal exposure to low doses of 2,3,7,8-tetrachlorodibenzo-p-dioxin on immune organs in rats. Toxicology 2000;154:123-33.
71. Vorderstrasse BA, Cundiff J, Lawrence BP. Developmental exposure to the potent aryl hydrocarbon receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin impairs the cellmediated immune response to infection with influenza A virus, but enhances elements of innate immunity. J Immunotoxicol 2004;1:103-12.
72. Vorderstrasse BA, Dearstyne EA, Kerkvliet NI. Influence of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the antigen-presenting activity of dendritic cells. Toxicol Sci 2003; 72:103-12.
73. Laupeze B, Amiot L, Sparfel L, et al. Polycyclic aromatic hydrocarbons affect functional differentiation and maturation of human monocyte-derived dendritic cells. J Immunol 2002;168:2652-8.
74. Ruby CE, Funatake CJ, Kerkvliet NI. 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) directly enhances the maturation and apoptosis of dendritic cells in vitro. J Immunotoxicol 2005;1:159-66.
75. Vorderstrasse BA, Kerkvliet NI. 2,3,7,8-tetrachlorodibenzo-p-dioxin affects the number and function of murine splenic dendritic cells and their expression of accessory molecules. Toxicol Appl Pharmacol 2001;171:117-25.
76. Ruby CE, Leid M, Kerkvliet NI. 2,3,7,8-tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-kappaB/Rel in dendritic cells: p50 homodimer activation is not affected. Mol Pharmacol 2002;62:722-8.
77. Lee JA, Hwang JA, Sung HN, et al. 2,3,7,8-tetrachlorodibenzo-p-dioxin modulates functional differentiation of mouse bone marrow-derived dendritic cells: downregulation of RelB by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Lett 2007;173:31-40.
78. Singh NP, Nagarkatti M, Nagarkatti PS. Role of dioxin response element and nuclear factor-kappa B motifs in 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated regulation of Fas and Fas ligand expression. Mol Pharmacol 2007;71:145-57.
79. Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008;453:65-71.
80. Haeryfar SM, DiPaolo RJ, Tscharke DC, et al. Regulatory T cells suppress CD8+ T cell responses induced by direct priming and cross-priming and moderate immunodominance disparities. J Immunol 2005;174: 3344-51.
81. Funatake CJ, Marshall NB, Steppan LB, et al. Cutting edge: activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin generates a population of CD4+ CD25+ cells with characteristics of regulatory T cells. J Immunol 2005;175:4184-8.
82. Kimura A, Naka T, Nohara K, et al. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 2008; 105:9721-6.
83. Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to envir onmental toxins. Nature 2008;453: 106-9.
84. Kashuba E, Kashuba V, Pokrovskaja K, et al. Epstein-Barr virus encoded nuclear protein EBNA-3 binds XAP-2, a protein associated with Hepatitis B virus X antigen. Oncogene 2000;19:1801-6.
85. Kashuba EV, Gradin K, Isaguliants M, et al. Regulation of transactivation function of the aryl hydrocarbon receptor by the Epstein-Barr virus-encoded EBNA-3 protein. J Biol Chem 2006;281:1215-23.
86. Hardell L, Lindström G, van Bavel B, et al. Adipose tissue concentrations of dioxins and dibenzofurans, titers of antibodies to Epstein-Barr virus early antigen and the risk for non-Hodgkin lymphoma. Environ Res 2001;87:99-107.
87. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801-12.
88. Stancek D, Kosecká G, Oltman M, et al. Links between prolonged exposure to xenobiotics, increased incidence of hepatopathies, immunological disturbances and exacerbation of latent Epstein-Barr virus infections. Int J Immunopharmacol 1995;17:321-8.
89. Beischlag TV, Luis Morales J, Hollingshead BD, et al. The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 2008;18:207-50.
90. Vorderstrasse BA, Cundiff J, Lawrence BP. A dose-response study of the effects of prenatal and lactational exposure to TCDD on the immune response to influenza A virus. J Toxicol Environ Health 2006;69:1-19.
91. Stockinger B. Beyond toxicity: aryl hydrocarbon receptor-mediated functions in the immune system. J Biol 2009;8:61.
92. Dewailly E, Ayotte P, Bruneau S, et al. Susceptibility to infections and immune status in Inuit infants exposed to organochlorines. Environ Health Perspect 2000;108:205-11.
93. ten Tusscher GN, Steerenberg PA, Van Loveren H, et al. Persistent hematologic and immunologic disturbances in 8-yearold Dutch children associated with perinatal dioxin exposure. Environ Health Perspect 2003;111:1519-23.
94. Dallaire F, Dewailly E, Muckle G, et al. Acute infections and environmental expos ure to organochlorines in Inuit infants from Nunavik. Environ Health Perspect 2004;112:1359-65.
95. Heilmann C, Grandjean P, Welhe P, et al. Reduced antibody responses to vaccinations in children exposed to polychlorinated biphenyls. PLOS Med 2006;3:e311.
96. Gehrs B, Samialowicz R. Persistent suppression of delayed-type hypersensitivity in adult F344 rats after perinatal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicology 1999;134:79-88.
97. Walker DB, Williams WC, Copeland CB, et al. Persistent suppression of contact hypersensitivity and altered T cell parameters in F344 rats exposed perinatally to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicology 2004;197:57-66.
98. Hockings JK, Thorne PA, Kemp MQ, et al. The ligand status of the aromatic hydrocarbon receptor modulates transcriptional activation of BRCA-1 promoter by estrogen. Cancer Res 2006;66:2224-32.
99. Tomatis L. The IARC monographs program: changing attitudes towards public health. Int J Occup Environ Health 2002; 8:144-52.
100. Steenland K, Bertazzi P, Baccarelli A, et al. Dioxin revisited: developments since the 1997 IARC classification of dioxin as a human carcinogen. Environ Health Perspect 2005;112:1265-8.
101. Danaei G, Vander Hoorn S, Lopez AD, et al. Comparative Risk Assessment collaborating group (Cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2003;366:1784-93.
102. Thompson J, Anthony H. The Health Effects of Waste Incinerators. 4th Report of the British Society for Ecological Medicine. 2nd edn, June 2008. http://www.ecomed.org.uk/content/Inciner atorReport_v3.pdf.
103. Schecter A, Gasiewicz T. Health hazard assessment of chlorinated dioxins and dibenzofurans contained in human milk. Chemosphere 1987;16:2147-54.
104. Schecter A, Startin J, Wright C, et al. Congener-specific levels of dioxins and dibenzofurans in US food and estimated daily dioxin toxic equivalent intake. Env Health Perspect 1994;102:962-6.
105. US Environmental Protection Agency. Health Assessment Document for 2,3,7,8 - tetrachlorodibenzo-p-dioxin and Related Compounds. Vol 1-3, Review Draft. Washington DC: US EPA Office of Research and Development (EPA/600/BP-92-001), 1994.
106. Belpomme D, Irigaray P, Sasco AJ, et al. The growing incidence of cancer: role of lifestyle and screening dectection. Int J Oncol 2007;30:1037-49.
107. Irigaray I, Newby JA, Clapp R, et al. Lifestyle-related factors and environmental agents causing cancer: an overview. Biomed Pharmacother 2007;61:640-58.
108. Clapp RW, Jacobs MM, Loechler EL. Environmental and occupational causes of cancer: new evidence 2005-2007. Rev Environ Health 2008;23:1-37.
109. Epstein SS. Cancer-Gate: How to win the losing cancer war. Amityville, NY: Baywood Publishing Company, Inc, 2005.
110. AIRTUM Working Group. Tumori infantili. Incidenza, sopravvivenza, andamenti temporali. Epidemiol Prev 2008;32:S1-112.
111. AIRTUM Working Group. New incidence mortality data 2003-2205. Epidemiol Prev 2009;33:S.
112. Puga A, Ma C, Marlowe JL. The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol 2009;77:713-22.
113. Ma C, Marlowe JL, Puga A. The aryl hydrocarbon receptor at the crossroads of multiple signaling pathways. EXS 2009;99:231-57.
114. Porta D, Milani S, Lazzarino AI, et al. Systematic review of epidemiological studies on health effects associated with management of solid waste. Environ Health 2009;8:60.
115. Irigaray P, Belpomme D. Basic properties and molecular mechanisms of exogenous chemical carcinogens. Carcinogenesis 2010;31:135-48.
116. Wittsiepe J, Fürst P, Schrey P, et al. PCDD/F and dioxin-like PCB in human blood and milk from German mothers. Chemosphere 2007;67:286-94.
117. Li J, Zhang L, Wu Y, et al. A national survey of polychlorinated dioxins, furans (PCDD/Fs) and dioxin-like polychlorinated biphenyls (dl-PCBs) in human milk in China. Chemosphere 2009;75:1236-42.
118. Tomatis L, Narod S, Yamasaki H. Trans-generation transmission of carcinogenic risk. Carcinogenesis 1992;13:145-51.
119. Knox EG. Roads, railways, and childhood cancers. J Epidemiol Community Health 2006;60:136-41.
120. Pacchierotti F, Ranaldi R, Eichenlaub-Ritter U, et al. Evaluation of aneugenic effects of bisphenol A in somatic and germ cells of the mouse. Mutat Res 2008;651:64-70.
121. Robaire B. Is it my grandparents' fault? Nat Med 2008;14:1186-7.
122. Soto AM, Vandenberg LN, Maffini MV, et al. Does breast cancer start in the womb? Basic Clin Pharmacol Toxicol 2008;102; 125-33.
123. Jedrychowski W, Perera F, Mrozek-Budzyn D, et al. Gender differences in fetal growth of newborns exposed prenatally to airborne fine particulate matter. Environ Res 2009;109:447-56.
124. Millstone E, Brunner E, White I. Plagiarism or protecting public health? Nature 1994;371:647-8.
125. Tomatis L, Huff J. Evolution of cancer etiology and primary prevention. Environ Health Perspect 2001;109:A458-60.
126. Sonnenschein C, Soto AM. Theories of carcinogenesis: an emerging perspective. Semin Cancer Biol 2008;18:372-7.
127. Epstein SS. The politics of cancer. JAMA 2000;284:442.